From “eat less, move more” to an industry of programs
In 2023, Novo Nordisk’s weight-loss drug Wegovy generated more than $4.5 billion in global sales, underscoring how medical weight loss programs are rapidly transforming the market. This shows that powerful medical treatments are reshaping weight loss programs. Thus, medical treatments now play a major role in sustainable weight loss. That number doesn’t just reflect demand; it captures a shift in how people think about losing weight. For decades, the dominant model was simple: eat less, move more, try harder. Now, weight loss
programs span everything from calorie-counting apps and structured diets to prescription medications and metabolic clinics. And yet, despite all this innovation, long-term success remains stubbornly rare. Commercial weight loss programs have been around for decades, and some of them do produce real results. WeightWatchers (now WW International) built an empire on its points system, designed to guide users toward lower-calorie foods without strict
prohibition. A 2015 randomized controlled trial published in The Lancet found that WeightWatchers participants lost about twice as much weight over 12 months. Those given standard care lost less. That sounds impressive. It is, to a point. But zoom out, and the picture gets
murkier. According to a 2018 meta-analysis in The BMJ, most structured diet programs lead to meaningful weight loss at six months. But the differences mostly disappear by year one. People regain weight.
Biology, adherence, and the limits of calorie math
Often gradually, sometimes quickly. The problem isn’t that these programs are ineffective in principle. It’s that they rely heavily on sustained behavioral compliance, which is notoriously fragile. Kevin Hall, a senior investigator at the National Institutes of Health, has spent years studying metabolism. His controlled feeding studies
show that while calorie reduction reliably produces weight loss, the body responds with hormonal changes that increase hunger and decrease energy expenditure. In plain terms, your body pushes back. That’s why adherence fades. Not because people are lazy, but because biology
intervenes. Many traditional programs treat weight loss as a math problem: calories in versus calories out. That framework still matters, but it ignores variables like sleep, stress, and food environment. Shift workers, for instance,
The GLP-1 era and the rise of medical weight loss subscriptions
face significantly higher obesity rates. A 2019 study in Obesity Reviews linked irregular sleep patterns to disrupted appetite hormones, including leptin and ghrelin. No points system accounts for that. The biggest disruption in recent years hasn’t come from a new diet—it’s come from pharmacology. GLP-1 receptor agonists, originally developed for type 2 diabetes, are
now at the center of many modern weight loss programs. Drugs like semaglutide (Wegovy) and tirzepatide (marketed as Zepbound by Eli Lilly) mimic appetite hormones. They help control hunger and fullness. In a 2021 trial published in The New England Journal
of Medicine, participants taking semaglutide lost an average of 14.9% of their body weight over 68 weeks. That’s not marginal. It’s comparable to outcomes previously seen only with bariatric surgery. This has spawned an entire industry of medical weight loss programs. Companies like Calibrate, Found, and Sequence (acquired by WeightWatchers in 2023) combine telehealth
consultations, coaching, and prescriptions into subscription-based models. Some offer metabolic testing, continuous glucose monitoring, or personalized nutrition plans layered on
top of medication. But there’s a catch. These drugs are expensive—often over $1,000 per month without insurance—and access remains uneven. And when patients stop taking them, weight regain is common. A 2022 follow-up study showed that participants regained about
Digital behavior design and the data gap
two-thirds of lost weight within a year of discontinuing semaglutide. So the question becomes less about whether these programs work. It becomes more about how long someone can realistically stay on them. Not all innovation
is pharmaceutical. Digital health platforms have tried to tackle the adherence problem from another angle: behavior design. Noom, for example, blends calorie tracking with psychology-based coaching. It emphasizes cognitive behavioral techniques—identifying triggers, reframing habits, building awareness. The company cites internal data suggesting
users lose an average of 5% of body weight over 16 weeks, though independent verification of these figures is limited. That’s a recurring issue in this category: promising models, but thin public data. Apps like MyFitnessPal (owned by Francisco Partners
since 2020) and Lose It! rely on tracking and feedback loops. Others, like StepBet, introduce financial incentives—users bet their own money on meeting activity goals. There’s some evidence this works. A 2016 study
Why coaching and support still matter
in JAMA Internal Medicine found that financial incentives increased physical activity levels in the short term. Long-term effects were less clear. Accountability helps. But it doesn’t solve everything. One of the more consistent findings across studies is that human support improves outcomes. Programs that include regular coaching—whether through group meetings or one-on-one sessions—tend to outperform self-guided plans. This was true in the Diabetes
In the NIH-funded Diabetes Prevention Program, participants got intensive lifestyle coaching. They cut their risk of type 2 diabetes by 58% over three years. That result had less to do with any specific diet
The food environment and why population outcomes lag
and more to do with sustained engagement. You might expect better science, better tools, and better drugs to dramatically improve weight loss outcomes across the population. They haven’t.
Adult obesity prevalence in the United States was about 30.5% in 1999–2000, according to the CDC. By 2017–2018, it had risen to 42.4%. More recent estimates suggest it continues to hover above 40%. So what’s going on? Weight loss programs operate within
a broader food environment that hasn’t gotten any easier to navigate. Ultra-processed foods—linked to increased calorie intake in NIH studies—are cheap, accessible, and engineered for overconsumption. Even
Toward hybrid models, with sustainability as the constraint
the best-designed program struggles against that backdrop. There’s also a tendency to search for a universal answer: the best diet, the best app, the best drug. That framing misses something obvious. People respond differently. Genetics, medical conditions, income, schedule—all of it shapes what’s realistic. Bariatric surgery, for example, remains the most
effective intervention for severe obesity, with patients often losing 25–35% of body weight and maintaining much of it long term, according to the American Society for Metabolic and Bariatric Surgery. But it’s invasive,
and not appropriate for everyone. Meanwhile, some individuals do succeed with relatively simple interventions: walking more, cooking at home, reducing sugary drinks. It’s less dramatic, but it
happens. The next phase of weight loss programs will likely be hybrid. Medication plus coaching. Data tracking plus human support. Personalized plans informed by biomarkers, not just calorie targets. Companies are already moving in this
direction. Eli Lilly is investing heavily in next-generation incretin drugs. WW is repositioning itself as a “weight health” platform, integrating clinical care with its traditional community model. Even fitness companies are exploring partnerships with
